HCA Healthcare Inc. (HCA), one of America's largest hospital operators, delivered a classic case of mixed quarterly results on Tuesday that somehow managed to send shares surging to new highs. Welcome to the wonderful world of earnings season, where beating profit expectations matters more than missing revenue targets.

The Nashville-based hospital chain posted total revenues of $19.513 billion for the fourth quarter of 2025, marking a solid 6.7% jump from last year. That sounds impressive until you realize analysts were expecting $19.67 billion, so HCA technically came up short on the top line.

But here's where things get interesting. Adjusted earnings came in at $8.01 per share, absolutely demolishing the consensus estimate of $7.43 and representing a massive leap from the $6.22 reported a year earlier. Net income hit $1.878 billion, or $8.14 per share, compared to $1.438 billion, or $5.63 per share, in the same quarter last year.

The quarter included a little bonus: $41 million in gains from facility sales, adding about $0.13 per diluted share, primarily from unloading a hospital in Indiana.

Hospital Traffic Patterns

Digging into the operational numbers, same-facility admissions climbed 2.4% in the quarter, while equivalent admissions increased 2.5%. Emergency room visits edged up just 0.5%, suggesting people weren't exactly flooding into ERs. Inpatient surgeries stayed flat, and outpatient surgeries dipped slightly by 0.5%.

The company generated adjusted EBITDA of $4.114 billion, a healthy increase from $3.712 billion the previous year. Operating cash flow came in at $2.359 billion, though that was actually down from $2.559 billion in Q4 2024.

"We finished 2025 with strong performance consistent with previous quarters. Our investments in network expansion, workforce development, and advancing clinical capabilities further strengthened the HCA Healthcare system," said CEO Sam Hazen.

The Big Buyback Announcement

Here's where Tuesday's announcement really grabbed attention. HCA Healthcare authorized a new share repurchase program worth up to $10 billion. To put that in perspective, the company's current market cap sits around $103 billion, meaning this buyback represents roughly 10% of all outstanding shares. That's not a token gesture—it's a serious vote of confidence from management about the company's cash generation and future prospects.

Looking Ahead to 2026

The fiscal 2026 outlook tells a more cautious story. HCA expects earnings between $29.10 and $31.50 per share, with the midpoint sitting close to the analyst consensus of $29.54. Revenue guidance came in at $76.5 billion to $80 billion, compared to Wall Street's $79.08 billion estimate.

Management is projecting adjusted EBITDA between $15.55 billion and $16.45 billion, with net income expected in the $6.495 billion to $7.035 billion range.

On the conference call, executives highlighted some meaningful headwinds ahead. They're anticipating a $600 million to $900 million adverse impact related to health insurance exchanges, plus a $250 million to $450 million decline in net benefits from supplemental payments in 2026. That's potentially up to $1.35 billion in combined pressure.

Despite the cautious guidance, investors clearly focused on the earnings beat and that massive buyback authorization. HCA Healthcare shares jumped 11.29% to $525.69 on Tuesday, hitting a fresh 52-week high.